ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes <i>BRCA1</i> and <i>BRCA2</i>, with many more potential applications under study and in clinical trials...
Main Authors: | Nicholas R. Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Kolinsky, Gareth J. Williams, Pinaki Bose, Susan P. Lees-Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/687 |
Similar Items
-
Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01) -
OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01) -
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01) -
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
by: Atlal eAbu-Sanad, et al.
Published: (2015-07-01) -
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)